stockrow
Friday 6 November 2026
Export GUTS’s income statement to Excel — free account
Fractyl Health, Inc.
GUTS Healthcare Biotechnology
Fractyl Health, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $93,000.00, down 22.5% from fiscal 2023.
- Revenue
- −57.1%
- EPS
- +71.9%
- Free cash flow
- +25.3%
- Total debt
- +1.54%
Quarter to June 2026, against a year earlier
0.94
0.04
+4.44%
Follow GUTS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 0 | 0 | — | 0 | (22.5%) | 1 | 1 | 28 | +361.2% | |
| Gross margin, % | — | — | — | — | — | — | — | 35.83 | 46.24 | — | 46.24 | +10.4 pt | ||||||
| EBT | — | — | — | — | — | — | (46) | (77) | (69) | (141) | (106) | +44.8% | ||||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | (64,242.50) | (73,864.52) | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | (46) | (77) | (69) | (141) | (106) | +44.8% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.69 | 0.03 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | (280.23) | (543.70) | (19.45) | (22.33) | (10.56) | (57.0%) | ||||||
| Cash flow | — | — | — | — | — | — | (278.91) | (247.10) | (18.06) | (14.30) | (6.24) | (62.8%) | ||||||
| Capex | — | — | — | — | — | — | (0.34) | (2.07) | (0.49) | (0.09) | 0.00 | (36.1%) | ||||||
| Free cash flow | — | — | — | — | — | — | (279.25) | (249.17) | (18.55) | (14.39) | (6.24) | (62.8%) | ||||||
| Book value | — | — | — | — | — | — | (1,521.83) | (1,875.72) | 7.84 | 1.50 | (0.13) | n/m | ||||||
| Shares, m | — | — | — | — | — | — | 0 | 0 | 4 | 6 | 10 | +236.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | 225.02 | 964.08 | — | 127.89 | 594.5 | ||||||
| P/B | — | — | — | — | — | — | — | 0.00 | 3.15 | — | 0.00 | 1.6 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 405.25 | 562.98 | — | (51.61) | 484.1 | ||||||
| EV/FCF | — | — | — | — | — | — | — | (1.13) | (0.78) | — | 0.06 | (1.0) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (46) | (43) | (66) | (90) | (82) | +25.0% | |||||
| Capex | — | — | — | — | — | — | 0 | 0 | (2) | (1) | (1) | +115.1% | ||||||
| Free cash flow | — | — | — | — | — | — | (46) | (43) | (67) | (91) | (82) | +25.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 44 | 24 | 52 | 69 | 34 | +16.0% | |||||
| Net debt | — | — | — | — | — | — | (32) | 22 | (37) | (51) | (17) | +17.4% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | (252) | (325) | 28 | 9 | (2) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (137.45) | (74.55) | (122.85) | (146.75) | (122.8) pt | |||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | 0.00 | 32.65 | 46.32 | (744.17) | 1,063.04 | (744.2) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | 94 | 102 | 107 | 100 | — | +2.1% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2024 · latest quarter Dec 2024 · fundamentals updated 2 Nov 2026
Fractyl Health, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NCEL NewcelX Ltd. | $15.6M | — (loss-making) | — | — | n/m | −87.71% (below 0%: shrinking) | 0.00% | — | Compare |
| RADX Radiopharm Theranostics Limited - Sponsored ADR | $14.0M | — | — | — | — | −137.75% (below 0%: shrinking) | — | — | Compare |
| CASIF CASI Pharmaceuticals Inc. | $12.4M | — (loss-making) | — (loss-making) | −45.93% (below 0%: shrinking) | n/m | −23,251.69% (below 0%: shrinking) | 51.14% | (147.67%) | Compare |
| BOLT Bolt Biotherapeutics, Inc. | $12.3M | — (loss-making) | — (loss-making) | −99.72% (below 0%: shrinking) | n/m | +38.87% (above 0%: growing) | 100.00% | (167,480.00%) | Compare |
| DARE Dare Bioscience, Inc. | $12.3M | — (loss-making) | — (loss-making) | +984.43% (above 0%: growing) | n/m | −30.23% (below 0%: shrinking) | (70.56%) | (1,582.93%) | Compare |
| GUTS Fractyl Health, Inc. | $11.9M | — (loss-making) | — (loss-making) | −57.14% (below 0%: shrinking) | n/m | +25.34% (above 0%: growing) | 100.00% | 0.00% | |
| HIND Vyome Holdings, Inc. | $11.4M | — (loss-making) | — (loss-making) | −46.00% (below 0%: shrinking) | n/m | −195.04% (below 0%: shrinking) | 43.33% | (3,194.81%) | Compare |
| PBM Psyence Biomedical Ltd. | $11.2M | 0.1× | — | — | n/m | −707.20% (below 0%: shrinking) | — | 0.00% | Compare |
| AEON AEON Biopharma, Inc. | $9.4M | — (loss-making) | — | — | n/m | −76.85% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $12.3M | — | — | −45.96% | — | −112.73% | 43.33% | (865.30%) |
Pay and ownership Proxy statement filed 24 August 2026
Ownership
Directors and executive officers, together
8.36%
Entities affiliated with Nantahala
9.99%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement